
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/968049/publications.pdf Version: 2024-02-01



Ι μιςλ Γοςτλ

#	Article	lF	CITATIONS
1	Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?. Autoimmunity Reviews, 2020, 19, 102524.	2.5	231
2	The ClASsification for Psoriatic ARthritis (CASPAR) Criteria – A Retrospective Feasibility, Sensitivity, and Specificity Study: Table 1 Journal of Rheumatology, 2012, 39, 154-156.	1.0	125
3	Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD Open, 2015, 1, e000097.	1.8	103
4	Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clinical Rheumatology, 2012, 31, 711-715.	1.0	100
5	Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clinical Rheumatology, 2014, 33, 833-839.	1.0	98
6	Identification of the Clinical Features Distinguishing Psoriatic Arthritis and Fibromyalgia. Journal of Rheumatology, 2012, 39, 849-855.	1.0	94
7	Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmunity Reviews, 2014, 13, 1220-1229.	2.5	86
8	Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clinical Rheumatology, 2016, 35, 1683-1689.	1.0	83
9	Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. Autoimmunity Reviews, 2015, 14, 1-9.	2.5	79
10	Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunologic Research, 2015, 61, 147-153.	1.3	70
11	Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence. Drugs in R and D, 2017, 17, 509-522.	1.1	69
12	Biological Treatments in Behçet's Disease: Beyond Anti-TNF Therapy. Mediators of Inflammation, 2014, 2014, 1-14.	1.4	68
13	Monogenic Autoinflammatory Syndromes: State of the Art on Genetic, Clinical, and Therapeutic Issues. International Journal of Rheumatology, 2013, 2013, 1-15.	0.9	67
14	JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunologic Research, 2014, 58, 61-69.	1.3	65
15	Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clinical Rheumatology, 2014, 33, 273-276.	1.0	64
16	Psoriatic arthritis and psoriasis: differential diagnosis. Clinical Rheumatology, 2016, 35, 1893-1901.	1.0	64
17	Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study. Journal of Rheumatology, 2019, 46, 904-911.	1.0	58
18	Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. Autoimmunity Reviews, 2015, 14, 90-97.	2.5	55

#	Article	IF	CITATIONS
19	Drug Retention Rates and Treatment Discontinuation among Anti-TNF- <i>α</i> Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice. Mediators of Inflammation, 2014, 2014, 1-7.	1.4	49
20	Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease. Autoimmunity Reviews, 2019, 18, 565-575.	2.5	49
21	Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress. Frontiers in Immunology, 2018, 9, 2363.	2.2	46
22	Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clinical Rheumatology, 2018, 37, 579-586.	1.0	43
23	Simple clinical indicators for early psoriatic arthritis detection. SpringerPlus, 2014, 3, 759.	1.2	42
24	Psoriatic disease treatment nowadays: unmet needs among the "jungle of biologic drugs and small molecules― Clinical Rheumatology, 2018, 37, 1739-1741.	1.0	42
25	The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clinical Rheumatology, 2011, 30, 1063-1067.	1.0	39
26	Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opinion on Pharmacotherapy, 2017, 18, 1557-1567.	0.9	39
27	From autoinflammation to autoimmunity: old and recent findings. Clinical Rheumatology, 2018, 37, 2305-2321.	1.0	39
28	Interaction between microbiome and host genetics in psoriatic arthritis. Autoimmunity Reviews, 2018, 17, 276-283.	2.5	38
29	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. Autoimmunity Reviews, 2021, 20, 102738.	2.5	38
30	Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvascularity in the joints of psoriatic arthritis. Clinical Rheumatology, 2015, 34, 1903-1912.	1.0	36
31	Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clinical Rheumatology, 2015, 34, 1571-1580.	1.0	36
32	Emerging drugs for psoriatic arthritis. Expert Opinion on Emerging Drugs, 2016, 21, 69-79.	1.0	36
33	Effectiveness and safety of ustekinumab in naÃ ⁻ ve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. Clinical Rheumatology, 2018, 37, 397-405.	1.0	36
34	New Developments in Magnetic Resonance Imaging of the Nail Unit. Journal of rheumatology Supplement, The, 2012, 89, 49-53.	2.2	35
35	Blockade of intra-articular TNF in peripheral spondyloarthritis: Its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine, 2013, 80, 165-170.	0.8	35
36	Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study. Journal of Rheumatology, 2016, 43, 2149-2154.	1.0	35

#	Article	IF	CITATIONS
37	The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clinical Rheumatology, 2014, 33, 543-547.	1.0	34
38	Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study. Rheumatology International, 2020, 40, 951-958.	1.5	34
39	Magnetic Resonance Imaging of Nail Unit in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2009, 83, 42-45.	2.2	33
40	Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis. Joint Bone Spine, 2014, 81, 190-192.	0.8	31
41	Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opinion on Biological Therapy, 2015, 15, 641-650.	1.4	31
42	Psoriatic Disease 10 Years Later. Journal of Rheumatology, 2017, 44, 1298-1301.	1.0	31
43	An update on pathogenesis of psoriatic arthritis and potential therapeutic targets. Expert Review of Clinical Immunology, 2019, 15, 823-836.	1.3	31
44	Efficacy of tocilizumab in a patient with refractory psoriatic arthritis. Clinical Rheumatology, 2014, 33, 1355-1357.	1.0	30
45	The Definition and Measurement of Axial Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2015, 93, 40-42.	2.2	30
46	Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2016, 12, 315-331.	1.3	30
47	Interleukin-17A (IL-17A): A silent amplifier of COVID-19. Biomedicine and Pharmacotherapy, 2021, 142, 111980.	2.5	30
48	Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. Clinical Rheumatology, 2015, 34, 1817-1820.	1.0	29
49	Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints. Journal of rheumatology Supplement, The, 2015, 93, 48-52.	2.2	29
50	PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. Clinical Rheumatology, 2016, 35, 501-505.	1.0	28
51	Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: An Italian bicentric study. PLoS ONE, 2018, 13, e0205506.	1.1	28
52	Untangling the Web of Systemic Autoinflammatory Diseases. Mediators of Inflammation, 2014, 2014, 1-15.	1.4	25
53	Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-217251.	0.5	25
54	Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort. Annals of the Rheumatic Diseases, 2021, 80, e46-e46.	0.5	25

#	Article	IF	CITATIONS
55	Psoriatic arthritis: advances in pharmacotherapy based on molecular target. Expert Opinion on Pharmacotherapy, 2013, 14, 2311-2313.	0.9	24
56	Osteoporosis and Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2012, 89, 36-38.	2.2	23
57	Association between small dense LDL and sub-clinical atherosclerosis in patients with psoriatic arthritis. Clinical Rheumatology, 2016, 35, 2023-2029.	1.0	22
58	Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study. International Journal of Rheumatic Diseases, 2017, 20, 103-108.	0.9	22
59	Psoriatic arthritis and TNF inhibitors: advances on effectiveness and toxicity. Expert Opinion on Biological Therapy, 2015, 15, 1-2.	1.4	21
60	Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints. Clinical Rheumatology, 2017, 36, 391-399.	1.0	21
61	Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset "sine psoriasis― Clinical Rheumatology, 2019, 38, 2547-2552.	1.0	21
62	Symptomatic psoriatic dactylitis is associated with ultrasound determined extra-synovial inflammatory features and shorter disease duration. Clinical Rheumatology, 2019, 38, 903-911.	1.0	21
63	Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment. Rheumatology and Therapy, 2020, 7, 867-882.	1.1	21
64	Metabolic Syndrome and psoriatic arthritis: considerations for the clinician. Expert Review of Clinical Immunology, 2020, 16, 409-420.	1.3	21
65	Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies. Therapeutic Advances in Chronic Disease, 2015, 6, 328-338.	1.1	20
66	Small molecules and antibodies for the treatment of psoriasis: a patent review (2010–2015). Expert Opinion on Therapeutic Patents, 2016, 26, 757-766.	2.4	20
67	Role of thymopoiesis and inflamm-aging in COVID-19 phenotype. Pediatrics and Neonatology, 2020, 61, 364-365.	0.3	20
68	Predominant ultrasonographic extracapsular changes in symptomatic psoriatic dactylitis: results from a multicenter cross-sectional study comparing symptomatic and asymptomatic hand dactylitis. Clinical Rheumatology, 2020, 39, 1157-1165.	1.0	19
69	Ultrasonographic Evidence of Predominance of Acute Extracapsular and Chronic Intrasynovial Patterns in 100 Cases of Psoriatic Hand Dactylitis. Journal of Rheumatology, 2020, 47, 227-233.	1.0	18
70	<p>An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis</p> . Biologics: Targets and Therapy, 2020, Volume 14, 53-75.	3.0	17
71	Retention rates and identification of factors associated with anti-TNFα, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting. Clinical Rheumatology, 2020, 39, 2663-2670.	1.0	17
72	Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study. Clinical and Experimental Rheumatology, 2017, 35, 137-140.	0.4	17

#	Article	IF	CITATIONS
73	A machine-learning approach to cardiovascular risk prediction in psoriatic arthritis. Rheumatology, 2020, 59, 1767-1769.	0.9	16
74	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. Rheumatology, 2022, 61, 4124-4129.	0.9	16
75	Screening and Monitoring of Latent Tubercular Infection in Patients Taking Tumor Necrosis Factor-Â Blockers for Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2012, 89, 82-85.	2.2	15
76	Impact of 24Âmonths of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study. Clinical Rheumatology, 2016, 35, 1615-1618.	1.0	15
77	Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management. Drugs and Aging, 2019, 36, 909-925.	1.3	15
78	Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment. Clinical Rheumatology, 2019, 38, 2355-2362.	1.0	15
79	Pathogenesis of Psoriatic Arthritis. Critical Reviews in Immunology, 2019, 39, 361-377.	1.0	15
80	Psoriatic Disease: Clinical Staging. Journal of rheumatology Supplement, The, 2015, 93, 24-26.	2.2	14
81	Tackling the autoimmune side in Spondyloarthritis: A systematic review. Autoimmunity Reviews, 2020, 19, 102648.	2.5	13
82	May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?. Journal of Translational Medicine, 2020, 18, 489.	1.8	13
83	Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study. Clinical Rheumatology, 2017, 36, 1589-1593.	1.0	12
84	Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study. Frontiers in Pharmacology, 2019, 10, 1497.	1.6	12
85	A Multimodal Eye Assessment in Psoriatic Arthritis Patients sine-Psoriasis: Evidence for a Potential Association with Systemic Inflammation. Journal of Clinical Medicine, 2020, 9, 719.	1.0	12
86	Early Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2009, 83, 26-27.	2.2	11
87	Fragility Fractures in Patients with Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2015, 93, 36-39.	2.2	11
88	<p>Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis</p> . Open Access Rheumatology: Research and Reviews, 2019, Volume 11, 143-156.	0.8	10
89	Performance and calibration of the algorithm ASSIGN in predicting cardiovascular disease in Italian patients with psoriatic arthritis. Clinical Rheumatology, 2019, 38, 971-976.	1.0	10
90	Effectiveness of steroid injection for hand psoriatic dactylitis: results from a multicentre prospective observational study. Clinical Rheumatology, 2020, 39, 3383-3392.	1.0	10

LUISA COSTA

#	Article	IF	CITATIONS
91	The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. Scientific Reports, 2021, 11, 12455.	1.6	10
92	Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-α therapy. Clinical and Experimental Rheumatology, 2016, 34, 507-12.	0.4	10
93	Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2015, 93, 79-81.	2.2	9
94	Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate. Clinical Rheumatology, 2017, 36, 1797-1802.	1.0	8
95	Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art. Expert Opinion on Pharmacotherapy, 2020, 21, 785-796.	0.9	8
96	Dactylitis in enteropathic spondyloarthritis. Clinical and Experimental Rheumatology, 2016, 34, 842-847.	0.4	8
97	Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory joint diseases and autoinflammatory disorders. Advances in Rheumatology, 2021, 61, 45.	0.8	7
98	Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210903.	1.2	7
99	Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. Scientific Reports, 2022, 12, 7498.	1.6	7
100	Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group. Annals of the Rheumatic Diseases, 2021, 80, 1498-1501.	0.5	6
101	Musculoskeletal Ultrasound in Monitoring Clinical Response to Treatment in Acute Symptomatic Psoriatic Dactylitis: Results from a Multicentre Prospective Observational Study. Journal of Clinical Medicine, 2020, 9, 3127.	1.0	6
102	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. Clinical Rheumatology, 2022, 41, 641-647.	1.0	6
103	Mud-bath therapy and oral glucosamine sulfate in patients with knee osteoarthritis: a randomized, controlled, crossover study. Clinical and Experimental Rheumatology, 2016, 34, 618-24.	0.4	6
104	Alopecia areata in a patient with psoriatic arthritis and <scp>C</scp> rohn's disease receiving etanercept. International Journal of Rheumatic Diseases, 2014, 17, 219-220.	0.9	5
105	Can hydroxychloroquine be useful in the prevention of COVID-19? An Italian survey in dermatologic and rheumatologic patients already under treatment. Journal of the American Academy of Dermatology, 2020, 83, e77-e79.	0.6	5
106	Is there any association between psoriasis, psoriatic arthritis and thyroid autoimmunity?. Australasian Journal of Dermatology, 2021, 62, e207-e211.	0.4	5
107	Sensitivity to change and clinical correlations of the novel DACtylitis glObal Sonographic (DACTOS) score in psoriatic arthritis. Rheumatology, 2021, 60, 4103-4111.	0.9	5
108	Adult-onset Still's disease with elderly onset, results from a multicentre study. Clinical and Experimental Rheumatology, 2022, , .	0.4	5

#	Article	IF	CITATIONS
109	Response to: â€~Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa?' by Akpabio <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e143-e143.	0.5	4
110	Coeliac disease is a risk factor for the development of seronegative arthritis in patients with autoimmune thyroid disease. Rheumatology, 2021, 60, 2440-2447.	0.9	4
111	Use of Ultrasonography to Discriminate Psoriatic Arthritis from Fibromyalgia: A Post-Hoc Analysis of the ULISSE Study. Journal of Clinical Medicine, 2022, 11, 180.	1.0	4
112	Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement. Clinical Rheumatology, 2021, , 1.	1.0	3
113	Ultrasound Effectiveness of Steroid Injection for hand Psoriatic Dactylitis: Results from a Longitudinal Observational Study. Rheumatology and Therapy, 2021, 8, 1809-1826.	1.1	3
114	Association between Leeds Dactylitis Index and ultrasonographic features: a multicentre study on psoriatic hand dactylitis. Clinical and Experimental Rheumatology, 2020, 38, 1112-1117.	0.4	3
115	Scores versus clinical profiles in therapeutic decisions: a positive example from the Italian Medicines Agency (AIFA) decisions in the field of osteoporosis. Clinical Rheumatology, 2018, 37, 575-578.	1.0	1
116	Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future. Journal of Experimental Pharmacology, 2020, 12, 487-502.	1.5	1
117	Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study). Clinical and Experimental Rheumatology, 2021, 39, 938-946.	0.4	1
118	AB0761â€SECUKINUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN REAL LIFE: AN ITALIAN EXPERIENC 2019, , .	E.,	0
119	Autoimmune screening before adenovirus vector-based DNA vaccine in women may avoid underuse for all the subjects. Neurological Sciences, 2021, 42, 5421-5423.	0.9	0
120	The anti-drug antibodies detection: a valuable tool for clinical response loss in psoriatic patients?. Italian Journal of Dermatology and Venereology, 2020, , .	0.1	0
121	Effects of tumor necrosis factor-α inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitis. Clinical and Experimental Rheumatology, 2015, 33, 411-3.	0.4	0
122	Clinical effects of mud-bath therapy and oral glucosamine sulfate after 6 months of discontinuation in patients with knee osteoarthritis: results from a randomised, controlled, crossover study. Clinical and Experimental Rheumatology, 2017, 35, 169.	0.4	0
123	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
124	Patrick-FABER test in detecting active sacroiliitis in spondyloarthritis patients: a prospective study using magnetic resonance as reference standard. Clinical and Experimental Rheumatology, 0, , .	0.4	0
125	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. Clinical and Experimental Rheumatology, 0, , .	0.4	0
126	COVID-19 clinical spectrum in psoriatic arthritis patients on biologics and tsDMARDs: results from a cohort at an Italian epicentre of the pandemic's third wave. Clinical and Experimental Rheumatology, 0, , .	0.4	0

#	Article	IF	CITATIONS
127	COVID-19 clinical spectrum in psoriatic arthritis patients on biologics and tsDMARDs: results from a cohort at an Italian epicentre of the pandemic's third wave Clinical and Experimental Rheumatology, 2022, , .	0.4	о
128	Patrick-FABER test in detecting active sacroiliitis in spondyloarthritis patients: a prospective study using magnetic resonance as reference standard Clinical and Experimental Rheumatology, 2022, , .	0.4	0